[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618502":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":151,"collaborators":20,"id":153,"slug":20,"hasResults":154,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":20,"eligibilityCriteria":158,"healthyVolunteers":154,"sex":159,"minAge":160,"maxAge":20,"enrollmentInfo":161,"targetDuration":20,"studyType":164,"phases":165,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants receiving GSK5471713","EXPERIMENTAL","Participants will receive GSK5471713, according to their allocated dose level guided by the dose escalation study design.",[13],"Drug: GSK5471713",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","GSK5471713","GSK5471713 will be administered at different dose levels based on the dose escalation study design",[9],null,[22],{"name":23,"affiliation":5,"role":24},"GSK Clinical Trials","STUDY_DIRECTOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"US GSK Clinical Trials Call Center","CONTACT","877-379-3718","GSKClinicalSupportHD@gsk.com",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":30},"EU GSK Clinical Trials Call Center","+44 (0) 20 89904466",[35,56,70,84,98,113,127,141],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"GSK Investigational Site","RECRUITING","La Jolla","California","92093","United States",{"type":43,"coordinates":44},"Point",[45,46],-117.2742,32.84727,{"lat":46,"lon":45},[49,50,53],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":51,"role":28,"phone":52,"phoneExt":20,"email":30},"EU GSK Clinical Trials Call Centre","+44 (0) 20 8990 4466",{"name":54,"role":55,"phone":20,"phoneExt":20,"email":20},"Rana McKay","PRINCIPAL_INVESTIGATOR",{"facility":36,"status":37,"city":57,"state":58,"zip":59,"country":41,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Grand Rapids","Michigan","49546",{"type":43,"coordinates":61},[62,63],-85.66809,42.96336,{"lat":63,"lon":62},[66,67,68],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":51,"role":28,"phone":52,"phoneExt":20,"email":30},{"name":69,"role":55,"phone":20,"phoneExt":20,"email":20},"Emerson Lim",{"facility":36,"status":37,"city":71,"state":72,"zip":73,"country":41,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Philadelphia","Pennsylvania","19107",{"type":43,"coordinates":75},[76,77],-75.16362,39.95238,{"lat":77,"lon":76},[80,81,82],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":51,"role":28,"phone":52,"phoneExt":20,"email":30},{"name":83,"role":55,"phone":20,"phoneExt":20,"email":20},"Kevin Zarrabi",{"facility":36,"status":37,"city":85,"state":86,"zip":87,"country":41,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"West Valley City","Utah","84119",{"type":43,"coordinates":89},[90,91],-112.00105,40.69161,{"lat":91,"lon":90},[94,95,96],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":51,"role":28,"phone":52,"phoneExt":20,"email":30},{"name":97,"role":55,"phone":20,"phoneExt":20,"email":20},"Jose Pacheco",{"facility":36,"status":37,"city":99,"state":100,"zip":101,"country":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Toronto","Ontario","M5G 2M9","Canada",{"type":43,"coordinates":104},[105,106],-79.39864,43.70643,{"lat":106,"lon":105},[109,110,111],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":51,"role":28,"phone":52,"phoneExt":20,"email":30},{"name":112,"role":55,"phone":20,"phoneExt":20,"email":20},"Srikala Sridhar",{"facility":36,"status":37,"city":114,"state":115,"zip":116,"country":102,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Montreal","Quebec","H4A 3J1",{"type":43,"coordinates":118},[119,120],-73.58781,45.50884,{"lat":120,"lon":119},[123,124,125],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":51,"role":28,"phone":52,"phoneExt":20,"email":30},{"name":126,"role":55,"phone":20,"phoneExt":20,"email":20},"Ramy Saleh",{"facility":36,"status":37,"city":128,"state":20,"zip":129,"country":130,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Tokyo","104-0045","Japan",{"type":43,"coordinates":132},[133,134],139.69171,35.6895,{"lat":134,"lon":133},[137,138,139],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":51,"role":28,"phone":52,"phoneExt":20,"email":30},{"name":140,"role":55,"phone":20,"phoneExt":20,"email":20},"Kazuki Sudo",{"facility":36,"status":37,"city":128,"state":20,"zip":142,"country":130,"cosmosGeoPoint":143,"geoPoint":145,"contacts":146},"135-8550",{"type":43,"coordinates":144},[133,134],{"lat":134,"lon":133},[147,148,149],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":51,"role":28,"phone":52,"phoneExt":20,"email":30},{"name":150,"role":55,"phone":20,"phoneExt":20,"email":20},"Yuji Miura",{"type":152,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100618502",false,"NCT07332455","First-Time-in-Human Study of GSK5471713 in Adults With mCRPC","A Phase 1\u002F2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)","Inclusion Criteria:\n\n* Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate.\n* Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT).\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.\n* Progression on ADT and \\>=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC) and received 1-2 prior taxane based chemotherapy regimens.\n\nExclusion Criteria:\n\n* Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate, or any histology different from adenocarcinoma.\n* Impaired cardiac function or clinically significant cardiac disease.\n* Any significant medical condition, such as uncontrolled infection or clinically significant laboratory abnormality.\n* Prior therapy with Androgen receptor (AR) Degrader targeted therapy. Other protocol-defined inclusion\u002Fexclusion criteria apply.","MALE","18 Years",{"count":162,"type":163},54,"ESTIMATED","INTERVENTIONAL",[166,167],"PHASE1","PHASE2","This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit\u002Frisk of GSK5471713 given as a monotherapy in mCRPC.",[170],"Neoplasms, Prostate",[172,173,17,174],"Metastatic castration-resistant prostate cancer","First-Time-in-Human","Prostate cancer","2026-06-17",{"date":177,"type":178},"2026-06-18","ACTUAL",{"date":180,"type":178},"2026-02-10",{"date":182,"type":163},"2030-03-26",{"name":5,"class":6},8]